Treatment of Metastatic Equine Melanoma with a Plasmid DNA Vaccine Encoding Streptococcus Pyogenes EMM55 Protein

被引：13

作者：

Brown, Elizabeth L. ^{[1
]}

Ramiya, Vijayakumar K. ^{[2
]}

Wright, Cara A. ^{[1
]}

Jerald, Maya M. ^{[2
]}

Via, Angela D. ^{[2
]}

Kuppala, Venkata N. ^{[2
]}

Hazell, William S. ^{[2
]}

Lawman, Patricia D. ^{[2
]}

Lawman, Michael J. ^{[2
]}

机构：

[1] Braden River Equine, West Coast Vet Ctr, Sarasota, FL USA

[2] Moiphogenesis Inc, Tampa, FL 33614 USA

来源：

JOURNAL OF EQUINE VETERINARY SCIENCE | 2014年 / 34卷 / 05期

关键词：

Equine; Melanoma; Plasmid; Vaccine; Emm55; Regression; TYROSINASE; HORSES;

D O I：

10.1016/j.jevs.2013.11.012

中图分类号：

S85 [动物医学（兽医学）];

学科分类号：

0906 ;

摘要：

A 19-year-old castrated male Arab/Quarter horse presented with an extensive history of cutaneous metastatic melanoma. Over a period of 8 months, a total of 8 doses of plasmid DNA vaccine expressing the Streptococcus pyogenes emm55 gene (pAc/emm55) were administered intratumorally at 300 mu g/dose via a needless injector. Upon completion of the vaccination protocol, the size of the injected lesions, on average, were reduced by 40.3% from the initial size measurements. Lesions that were not injected were reduced by 47.6%. The overall reduction in total tumor burden was 42.3%. Tumor regression was also associated with the augmentation of antimelanoma IgG antibody response, thus implying that an induction of an effective antimelanoma response would be of great advantage in the management of equine melanoma. (C) 2014 Elsevier Inc. All rights reserved.

引用

页码：704 / 708

页数：5

共 17 条

[1]

Bergman PJ, 2003, CLIN CANCER RES, V9, P1284

[2]

Burden K., 2011, Young Scientists J, V4, P75, DOI [10.4103/0974-6102.92207, DOI 10.4103/0974-6102.92207]

[3]

GOETZ TE, 1990, J AM VET MED ASSOC, V196, P449

[4]

GOETZ TE, 1993, COMP CONT EDUC PRACT, V15, P608

[5] Well-defined melanoma antigens as progression markers for melanoma: Insights into differential expression and host response based on stage [J].

Hodi, FS .

CLINICAL CANCER RESEARCH, 2006, 12 (03) :673-678

[6] Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. [J].

Kantoff, Philip W. ;

Higano, Celestia S. ;

Shore, Neal D. ;

Berger, E. Roy ;

Small, Eric J. ;

Penson, David F. ;

Redfern, Charles H. ;

Ferrari, Anna C. ;

Dreicer, Robert ;

Sims, Robert B. ;

Xu, Yi ;

Frohlich, Mark W. ;

Schellhammer, Paul F. ;

Ahmed, T. ;

Amin, A. ;

Arseneau, J. ;

Barth, N. ;

Bernstein, G. ;

Bracken, B. ;

Burch, P. ;

Caggiano, V. ;

Chin, J. ;

Chodak, G. ;

Chu, F. ;

Corman, J. ;

Curti, B. ;

Dawson, N. ;

Deeken, J. F. ;

Dubernet, T. ;

Fishman, M. ;

Flanigan, R. ;

Gailani, F. ;

Garbo, L. ;

Gardner, T. ;

Gelmann, E. ;

George, D. ;

Godfrey, T. ;

Gomella, L. ;

Guerra, M. ;

Hall, S. ;

Hanson, J. ;

Israeli, R. ;

Jancis, E. ;

Jewett, M. A. S. ;

Kassabian, V. ;

Katz, J. ;

Klotz, L. ;

Koeneman, K. ;

Koh, H. ;

Kratzke, R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (05) :411-422

[7]

LANCEFIELD RC, 1962, J IMMUNOL, V89, P307

[8] Development of Immunologic Assays to Measure Response in Horses Vaccinated with Xenogeneic Plasmid DNA Encoding Human Tyrosinase [J].

Lembcke, Luis M. ;

Kania, Stephen A. ;

Blackford, James T. ;

Trent, Dianne J. ;

Odoi, Agricola ;

Grosenbaugh, Deborah A. ;

Fraser, Darrilyn G. ;

Leard, Timothy ;

Phillips, Jeffrey C. .

JOURNAL OF EQUINE VETERINARY SCIENCE, 2012, 32 (10) :607-615

[9] Supermolecular architecture of a polypseudo-rotaxane:: [Cd(BPE)(α-Mo8O26)][Cd(BPE)(DMF)4]•2DMF (BPE=1,2-bis(4-pyridyl)ethane, DMF = N,N-dimethylformamide) [J].

Liao, JH ;

Juang, JS ;

Lai, YC .

CRYSTAL GROWTH & DESIGN, 2006, 6 (02) :354-356

[10] A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr) [J].

Meyer, RG ;

Britten, CM ;

Siepmann, U ;

Petzold, B ;

Sagban, TA ;

Lehr, HA ;

Weigle, B ;

Schmitz, M ;

Mateo, L ;

Schmidt, B ;

Bernhard, H ;

Jakob, T ;

Hein, R ;

Schuler, G ;

Schuler-Thurner, B ;

Wagner, SN ;

Drexler, I ;

Sutter, G ;

Arndtz, N ;

Chaplin, P ;

Metz, J ;

Enk, A ;

Huber, C ;

Wölfel, T .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (05) :453-467

← 1 2 →